Should A Biosimilar Sponsor Do The 'Patent Dance?' It Depends On Many Things
Executive Summary
The amount of exclusivity remaining for a reference product, strength of an innovator's patents and risk of a preliminary injunction are factors that biosimilar sponsors should consider in deciding whether to follow the BPCIA's patent information and exchange procedures, one legal expert suggests.
You may also be interested in...
US FDA's Biosimilars Chief Leah Christl Plans Departure
A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.
Biosimilar Global Reference Standard Intrigues US FDA, But Many Questions Still To Answer
Scientific and legal issues still must be resolved before establishing single reference products for biosimilar development, US FDA official says.
Biosimilar Global Reference Standard Intrigues US FDA, But Many Questions Still To Answer
Scientific and legal issues still must be resolved before establishing single reference products for biosimilar development, US FDA official says.